Cosette Company Profile

What is the competitive landscape for COSETTE

COSETTE has one hundred and twenty-six approved drugs.

There are five US patents protecting COSETTE drugs.

There are seventy-six patent family members on COSETTE drugs in twenty-six countries and ninety-seven supplementary protection certificates in fourteen countries.

Summary for Cosette

International Patents:	76
US Patents:	5
Tradenames:	76
Ingredients:	70
NDAs:	126

Drugs and US Patents for Cosette

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Cosette	ETHYOL	amifostine	INJECTABLE;INJECTION	020221-001	Dec 8, 1995		DISCN	Yes	No
Cosette	MICONAZOLE 7 COMBINATION PACK	miconazole nitrate	CREAM, SUPPOSITORY;TOPICAL, VAGINAL	076585-001	Mar 26, 2004		DISCN	No	No
Cosette	MYKACET	nystatin; triamcinolone acetonide	CREAM;TOPICAL	062367-001	May 28, 1985		DISCN	No	No
Cosette	PROMETHAZINE HYDROCHLORIDE	promethazine hydrochloride	SUPPOSITORY;RECTAL	040428-001	Feb 5, 2002	AB	RX	No	Yes

Expired US Patents for Cosette

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Cosette	BENICAR	olmesartan medoxomil	TABLET;ORAL	021286-001	Apr 25, 2002	5,616,599*PED
Cosette	BENICAR HCT	hydrochlorothiazide; olmesartan medoxomil	TABLET;ORAL	021532-003	Jun 5, 2003	6,878,703*PED
Cosette	EVOXAC	cevimeline hydrochloride	CAPSULE;ORAL	020989-002	Jan 11, 2000	5,340,821
Cosette	WELCHOL	colesevelam hydrochloride	CAPSULE;ORAL	021141-001	May 26, 2000	6,066,678*PED

Paragraph IV (Patent) Challenges for COSETTE drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	Tablets	40 mg/12.5 mg and 40 mg/25 mL		2007-02-15
	Powder for Oral Suspension	1.875 g/Packet and 3.75 g/Packet		2010-04-09
	For Injection	500 mg/vial		2004-04-16
	Extended-release Tablets	12.5 mg		2006-01-19
	Tablets	10 mg/20 mg and 5 mg/40 mg		2008-03-31
	Tablets	20 mg/12.5 mg		2007-05-11
	Tablets	5 mg and 10 mg		2013-07-10
	Tablets	625 mg		2009-07-01
	Capsules	30 mg		2009-02-27
	Extended-release Tablets	6.25 mg		2006-02-24
	Tablets	5 mg/20 mg and 10 mg/40 mg		2008-02-11
	Tablets	5 mg, 20 mg and 40 mg		2006-04-25

International Patents for Cosette Drugs

Country	Patent Number	Estimated Expiration
China	1988915
Eurasian Patent Organization	032959
Hong Kong	1047881
New Zealand	707246

Supplementary Protection Certificates for Cosette Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0347066	2002C/039	Belgium		PRODUCT NAME: ESCITALOPRAM. OXALAT. (INN) ESCITALOPRAM; NATL. REGISTRATION NO/DATE: 7004 IE10 F 3 20020729; FIRST REGISTRATION: SE 17084 20011207
0443983	C00443983/03	Switzerland		PRODUCT NAME: VALSARTAN + AMLODIPINE + HYDROCHLOROTHIAZIDE; REGISTRATION NUMBER/DATE: SWISSMEDIC 59407 16.09.2009
1915993	C300625	Netherlands		PRODUCT NAME: COMBINATIE BEVATTENDE ALISKIREN, OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN, EN AMLODIPINE, OF EEN FARMACEUATISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/11/686/001-056 20110414
0454511	SPC/GB99/008	United Kingdom		PRODUCT NAME: 2-N-BUTYL-4-SPIROCYCLOPENTANE-1-((2'-(TETRAZOL-5-YL)BIPHENYL-4-YL)METHYL)-2-IMIDAZOLIN-5-ONE)(GENERIC NAME IRBESARTAN) OPTIONALLY IN THE FORM OF ONE OF ITS SALTS AND HYDROCHLOROTHIAZIDE; REGISTERED: UK EU/1/98/086/001 19981015; UK EU/1/98/086/002 19981015; UK EU/1/98/086/003 19981015; UK EU/1/98/086/004 19981015; UK EU/1/98/086/005 19981015; UK EU/1/98/086/006 19981015

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Cosette

Pharmaceutical Competitive Landscape Analysis: COSETTE – Market Position, Strengths & Strategic Insights

In the ever-evolving pharmaceutical industry, staying ahead of the competition is crucial for success. Cosette Pharmaceuticals, a US-based specialty pharmaceutical company, has been making significant strides in recent years. Let's dive into a comprehensive analysis of Cosette's market position, strengths, and strategic insights to understand how they're navigating the competitive landscape.

The Rise of Cosette Pharmaceuticals

Cosette Pharmaceuticals has emerged as a notable player in the pharmaceutical industry, with a focus on branded pharmaceuticals in women's health, cardiology, and dermatology. The company's journey has been marked by strategic acquisitions and a commitment to innovation.

A Brief History

Cosette Pharmaceuticals has a rich history dating back over 100 years. However, its recent transformation began in December 2018 when Avista Capital Partners, a healthcare-focused private equity firm, made an initial investment in the company[4]. Since then, Cosette has undergone significant changes and growth under new executive management.

Product Portfolio Expansion

One of Cosette's key strengths lies in its rapidly expanding product portfolio. The company has successfully launched new and innovative products across its focus areas through a combination of R&D efforts, acquisitions, and licensing deals[4]. Some notable additions to their portfolio include:

1. Clomid®
2. Ambien® and Ambien CR®
3. Benicar®
4. Vyleesi®
5. Intrarosa®

Cosette's Market Position

Cosette Pharmaceuticals has been steadily strengthening its market position through strategic moves and partnerships. Let's examine some key aspects of their current standing in the pharmaceutical landscape.

Recent Acquisitions

In July 2024, Cosette made a significant move by acquiring Ambien® and Ambien CR® in the United States from Sanofi US[1]. This acquisition not only expanded Cosette's product portfolio but also demonstrated the company's ability to execute complex carve-outs and integrate diverse products.

"We are excited at the addition of Ambien to our portfolio," stated Apurva Saraf, President and CEO of Cosette. "We continue to leverage our demonstrated, best-in-class capabilities in executing complex carve-outs and integrating diverse products."[1]

Financial Performance

While specific financial details are limited, the acquisition of Ambien® and Ambien CR® provides some insight into Cosette's market presence. According to IQVIA®, U.S. annual sales for these products for the 12 months ended April 2024 were $39 million[1]. This indicates a substantial market for Cosette's newly acquired products.

Strategic Partnerships

In July 2024, Cosette entered into a partnership with Hamilton Lane, a leading global private markets investment management firm. Funds managed by Hamilton Lane acquired a significant equity interest in Cosette, joining Avista Capital Partners in jointly controlling the company[4]. This partnership is expected to enhance Cosette's ability to drive further growth through investments in R&D and business development.

Cosette's Strengths and Competitive Advantages

Cosette Pharmaceuticals has several strengths that contribute to its competitive position in the pharmaceutical market. Let's explore these advantages in detail.

Diverse Product Portfolio

Cosette's product portfolio spans multiple therapeutic areas, including women's health, cardiology, and dermatology. This diversification helps mitigate risks associated with reliance on a single product or therapeutic area.

Manufacturing Capabilities

The company has a long history in quality manufacturing of complex dosage forms, including:

• Topical creams
• Ointments
• Oral liquids/solutions
• Suppositories

This expertise in manufacturing complex dosage forms gives Cosette a competitive edge in certain product categories.

Strong R&D Focus

Cosette has demonstrated a commitment to innovation through its R&D efforts. The company has successfully launched new and innovative products, indicating a robust pipeline and research capabilities[4].

Efficient Supply Chain

Cosette emphasizes the pursuit of the most efficient supply chain[7]. This focus on operational efficiency can lead to cost advantages and improved product availability.

Strategic Acquisitions and Licensing

The company has shown proficiency in executing complex carve-outs and integrating diverse products[1]. This skill in strategic acquisitions and licensing deals allows Cosette to rapidly expand its product portfolio and enter new markets.

Cosette's Growth Strategy

Cosette Pharmaceuticals has been implementing a multi-faceted growth strategy to strengthen its market position and drive future success. Let's examine the key components of this strategy.

Focus on Innovation

Innovation is at the core of Cosette's growth strategy. The company's tagline, "Innovating Every Day™," reflects this commitment[2]. Cosette invests in R&D to develop new products and improve existing ones, ensuring a robust pipeline for future growth.

Strategic Acquisitions

Cosette has demonstrated a keen eye for strategic acquisitions that complement its existing portfolio and expand its market reach. The recent acquisition of Ambien® and Ambien CR® is a prime example of this approach[1].

Expanding Branded Portfolio

While maintaining its presence in generic pharmaceuticals, Cosette has been actively expanding its branded product portfolio. This shift towards branded drugs can potentially lead to higher profit margins and increased market share in specific therapeutic areas.

Leveraging Manufacturing Expertise

Cosette's long history in manufacturing complex dosage forms provides a strong foundation for growth. The company continues to leverage this expertise to ensure high-quality products and explore opportunities in niche markets.

Partnerships and Collaborations

Cosette's recent partnership with Hamilton Lane[4] demonstrates the company's openness to strategic collaborations. Such partnerships can provide additional resources and expertise to fuel growth initiatives.

Cosette's Market Challenges and Opportunities

Like any pharmaceutical company, Cosette faces both challenges and opportunities in the current market landscape. Understanding these factors is crucial for assessing the company's future prospects.

Challenges

1. Intense Competition: The pharmaceutical industry is highly competitive, with both established players and new entrants vying for market share.

2. Regulatory Environment: Navigating the complex and ever-changing regulatory landscape in the pharmaceutical industry can be challenging and costly.

3. Patent Expirations: As with all pharmaceutical companies, Cosette must contend with patent expirations and the subsequent entry of generic competitors.

4. Pricing Pressures: Increasing scrutiny on drug pricing can impact profit margins and market access.

Opportunities

1. Expanding Therapeutic Areas: Cosette has the opportunity to enter new therapeutic areas through R&D or strategic acquisitions.

2. Digital Health Integration: Leveraging digital health technologies could enhance Cosette's product offerings and patient engagement.

3. Global Expansion: While currently focused on the US market, Cosette could explore opportunities for international expansion.

4. Personalized Medicine: Advances in genomics and personalized medicine present opportunities for targeted drug development.

Cosette's Competitive Intelligence Strategy

To maintain and improve its market position, Cosette likely employs a robust competitive intelligence strategy. While specific details of their approach are not publicly available, we can infer some key elements based on industry best practices and Cosette's actions.

Continuous Market Monitoring

Cosette likely maintains a constant watch on market trends, competitor activities, and regulatory changes. This ongoing surveillance helps the company identify threats and opportunities in real-time.

Competitor Analysis

Regular analysis of competitors' product portfolios, pipeline developments, and strategic moves is crucial. Cosette's successful acquisitions and portfolio expansions suggest a strong understanding of the competitive landscape.

Patent Landscape Assessment

Given the importance of intellectual property in the pharmaceutical industry, Cosette likely conducts thorough patent landscape assessments. This helps in identifying potential opportunities for product development or acquisition.

Leveraging Data Analytics

In today's data-driven world, Cosette probably utilizes advanced analytics tools to process vast amounts of market and competitive data. This can provide actionable insights for strategic decision-making.

Future Outlook for Cosette Pharmaceuticals

Based on Cosette's current position and strategic initiatives, the company appears well-positioned for future growth. Here are some key factors that could shape Cosette's future:

Continued Portfolio Expansion

With its recent acquisitions and focus on innovation, Cosette is likely to continue expanding its product portfolio. This could involve both in-house development and strategic acquisitions.

Enhanced R&D Capabilities

The partnership with Hamilton Lane is expected to provide additional resources for R&D investments[4]. This could lead to accelerated product development and innovation.

Potential Market Expansion

While currently focused on the US market, Cosette may explore opportunities for geographic expansion in the future, leveraging its growing product portfolio and manufacturing expertise.

Digital Transformation

As the healthcare industry increasingly embraces digital technologies, Cosette may invest in digital health solutions to complement its pharmaceutical offerings and enhance patient engagement.

Key Takeaways

1. Cosette Pharmaceuticals has significantly strengthened its market position through strategic acquisitions and portfolio expansion.

2. The company's diverse product portfolio, spanning women's health, cardiology, and dermatology, provides a competitive advantage.

3. Cosette's manufacturing expertise in complex dosage forms sets it apart in certain product categories.

4. The recent partnership with Hamilton Lane is expected to fuel further growth through increased R&D and business development investments.

5. Cosette's focus on innovation and strategic acquisitions positions it well for future growth in the competitive pharmaceutical landscape.

6. While facing industry-wide challenges such as pricing pressures and patent expirations, Cosette has opportunities in expanding therapeutic areas and leveraging digital health technologies.

7. The company's competitive intelligence strategy likely involves continuous market monitoring, competitor analysis, and leveraging data analytics for strategic decision-making.

FAQs

1. Q: What are Cosette Pharmaceuticals' main therapeutic areas? A: Cosette focuses primarily on women's health, cardiology, and dermatology.

2. Q: When did Avista Capital Partners invest in Cosette Pharmaceuticals? A: Avista Capital Partners made its initial investment in Cosette in December 2018.

3. Q: What significant acquisition did Cosette make in 2024? A: In July 2024, Cosette acquired Ambien® and Ambien CR® in the United States from Sanofi US.

4. Q: Who is the current President and CEO of Cosette Pharmaceuticals? A: Apurva Saraf is the current President and CEO of Cosette Pharmaceuticals.

5. Q: What is Cosette's tagline that reflects its commitment to innovation? A: Cosette's tagline is "Innovating Every Day™".

Sources cited: [1] https://www.businesswire.com/news/home/20240710788038/en/Cosette-Pharmaceuticals-Acquires-Ambien%C2%AE-and-Ambien-CR%C2%AE-Zolpidem-Tartrate-Tabs-from-Sanofi-US-in-the-US-Market [2] https://jobs.jobvite.com/cosettepharma/job/owWjufwZ [4] https://www.hamiltonlane.com/en-us/news/avista-capital-partners-cosette-pharma [7] https://cosettepharma.com